Valuation Update With 7 Day Price Move • 19h
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to ₩8,570, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩13,140, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 2.3% over the past three years. New Risk • Jun 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩151.7b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩151.7b market cap, or US$97.2m). New Risk • May 21
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 19
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩13,490, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 11% over the past three years. 공시 • May 15
HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion. HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,762,332
Price\Range: KRW 11150
Discount Per Security: KRW 111.5
Transaction Features: Rights Offering Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩19,410, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. 공시 • Mar 04
HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026 HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South Korea New Risk • Jan 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change). 공시 • May 09
HLB Pharmaceutical Co., Ltd. announced that it has received KRW 19.00000452 billion in funding from HLB Life Science Co., Ltd. On May 8, 2025, HLB Pharmaceutical Co., Ltd. closed the transaction. 공시 • Feb 26
HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025 HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South Korea New Risk • Nov 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Mar 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Mar 14
HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in funding On March 12, 2021, HLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) closed the transaction. 공시 • Feb 11
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in funding HLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) announced a private placement of series 14 non-guaranteed private equity convertible bonds for the gross proceeds of KRW 13,200,000,000 on February 10, 2021. The transaction will include participation from new investor, Faith 1 Fund. The bonds carry coupon rate of 0% and surface interest rate of 0% and will mature on March 12, 2024. The bonds are 100% convertible into 817,236 common shares representing 3.66% stake at a conversion price of KRW 16,152 per share. The conversion period will start on March 12, 2022 and end on February 12, 2024. The subscription date is February 10, 2021 and payment date is March 12, 2021. The transaction was approved by board of directors of the company. 공시 • Sep 11
Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd. On September 10, 2020, Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) closed the transaction. The company issued 4,154,511 shares for gross proceeds of KRW 18,632,981,835 in its second and final tranche. The company received KRW 48,632,978,215 in the transaction. 공시 • Sep 01
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from HLB Co., Ltd. and other investor Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 12 and series 13 unregistered non guaranteed private convertible bond for the gross proceeds of KRW 10,000,000,000 each for aggregate gross proceeds of KRW 20,000,000,000 on August 31, 2020. The transaction will include participation from new investor HLB Co., Ltd. (KOSDAQ:A028300) for series 12 bonds and new investor Jaram Fund 1 for series 13 bonds. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on October 30, 2023. The series 12 and series 13 bonds are 100% convertible into 1,494,992 common shares each at a conversion price of KRW 6,689 per share. The conversion period will start on October 30, 2021 and end on September 30, 2023. The subscription date is August 31, 2020 and payment date is October 30, 2020. The transaction was approved by board of directors of the company. 공시 • Jul 02
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from Ibest Investment Company Ltd., Hanyang Securities Co. Ltd., Investment Arm, EBEST Investment & Securities Co., Ltd. Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 11 unregistered coupon non guaranteed private convertible bond for the gross proceeds of KRW 20,000,000,000 on April 27, 2020. The transaction will include participation from Ibest Investment Company Ltd. and Hanyang Securities Co. Ltd., Investment Arm for KRW 10,000,000,000 each. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on June 29, 2023. The bonds are 100% convertible into 3,556,188 registered common shares of the company at conversion price of KRW 5,624 per share. The conversion period will start on June 29, 2021 and end on May 29, 2023. The payment date is June 29, 2020. The transaction was approved by board of directors of the company.